Genentech, a biotechnology company, has launched a direct-to-consumer program for its flu pill Xofluza. This move aims to make the medication more accessible to people who need it, especially those with weakened immune systems.
Xofluza is designed to treat patients with severe or critical COVID-19 cases, and Genentech hopes that this new program will increase access to the life-saving treatment for eligible individuals. The company will work closely with healthcare providers, pharmacies, and other partners to distribute Xofluza directly to consumers.
By expanding its reach beyond traditional healthcare channels, Genentech aims to help more people get the medical attention they need during flu season.
Source: https://www.cnbc.com/2025/10/16/genentech-launches-direct-to-consumer-program-for-flu-pill-xofluza.html